A federal district judge heard arguments on Tuesday regarding Amgen's subpoena of journalist Paul Goldberg, as the drugmaker attempted to force the journalist to testify about an article that spurred a shareholder lawsuit.
In 2007, Goldberg, publisher of The Cancer Letter, wrote an article about the termination of a clinical study of Aranesp -- the Amgen drug used to treat patients with kidney disease or undergoing chemotherapy. Amgen shareholders then filed a class action lawsuit that accused the drugmaker of failing to disclose details about the study.
Goldberg challenged the subpoena and U.S. District Judge Amit Mehta expects to issue a decision soon.
Read the full National Law Journal article